---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-025564"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:36:31.572939+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma FY2022 net loss $16.3M, revenue up 173% but cash falls to $85k

## Summary
- Revenue $969,783, +173% YoY, driven by contract services with Rgene.
- Net loss $16.3M vs $12.0M in FY2021, increase of 36%.
- Operating expenses $15.8M, up from $12.1M, due to stock-based comp, SG&A, R&D.
- Working deficit $2.8M vs $3.7M working capital; cash $85k vs $5.8M.
- Pipeline: Vitargus Phase II trials in Australia/Thailand; ADHD ABV-1505 Phase II enrolling.

## SEC filing metadata
- accession: 0001213900-23-025564
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023025564/0001213900-23-025564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023025564/ea176222-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-025564
- JSON: https://secwatch.observer/filing/0001213900-23-025564.json
- Plain text: https://secwatch.observer/filing/0001213900-23-025564.txt

## Key facts
- Earnings Releases
  ABVC BIOPHARMA, INC. reported the fiscal year ended December 31, 2022 results: revenue $969,783, net income $16,312,374.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $969,783
  - Net income: $16,312,374
  - Result: reported results
  source text: ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results FREMONT, CA, March 31, 2023 -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022. Full Year 2022 Financial Results All comparisons are made on a year-over-year basis. ● Revenues . We generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively. The increase of $613,986, or approximately 173%, was primarily caused by the increase in contract services with Rgene. ● Operating Expenses. Our operating expenses were $15,797,780 in the year ended December 31, 2022, as compared to $12,056,679 in the year ended December 31, 2021. Such increase in operating expenses was mainly attributable to the increase in stock-based compensation and selling, gene
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023025564/0001213900-23-025564-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.